6th RSC-BMCS FRAGMENT-BASED DRUG DISCOVERY MEETING - Vienna, Austria - March 5-7, 2017
The aim of the 6th RSC-BMCS Fragment-based Drug Discovery meeting will be to continue the focus on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programmes.
The Fragment series was started in 2007 and continues with the theme, having over three-quarters of the presentations focused on case studies. The conference will include successful examples from all types of fragment-based approaches, including high concentration, NMR, SPR and X-ray screening.
- Justin Bower, Beatson Institute, UK
- Dennis Breitsprecher, NanoTemper, Germany
- Phil Cox, AbbVie, United Stated
- Iwan de Esch, VU Amsterdam, The Netherlands
- Fredrik Edfeldt, AstraZeneca, Sweden
- Stephen W Fesik, Vanderbilt University, United States
- Michael Hennig, leadXpro, Switzerland
- Gerhard Klebe, University of Marburg, Germany
- Christel Menet, Confo Therapeutics, Belgium
- Paul Mortenson, Astex, UK
- Simon Osborne, MRC Technology, UK
- Christian Ottmann, University of Eindhoven, The Netherlands
- Siegfried Reich, eFFECTOR, United States
- Dominic Ryan, formerly Cubist, USA
- Gregg Siegal, ZoBio, The Netherlands
- Steffen Steurer, Boehringer Ingelheim, Austria
Mrs Maggi Churchouse
Tel: +44 (0)1359 221004
Registration Form (07/02/2017 - 149 KB)
SPRING MEETING: SMALL MOLECULES AND BIOLOGICALS IN CANCER IMMUNOTHERAPY - Utrecht, The Netherlands - March 17, 2017
This symposium will provide a bird’s eye perspective on the developments in immuno-oncology, from large biologics to small molecules.
Immunotherapy is generating strong excitement in the scientific community and in the clinic. For example, the recent development and clinical success of checkpoint inhibitors (PD-1 and CTLA-4), bispecifics (T-cell engagement) and T-cell replacement therapies has led to significantly improved therapies and new hope for many cancer patients. Currently available immuno-oncology therapeutics are mostly biologics (antibodies, proteins, engineered cells and oncolytic viruses). Modulation of the immune system with small molecules may offer several complementary and potentially synergistic advantages to the use of large biologicals. The latter is a strong stimulus for the development of novel small-molecule modulators by medicinal chemists working in cancer immunotherapy.
This symposium will provide a bird’s eye perspective on the developments in immuno-oncology, from large biologics to small molecules. Recent immunotherapy approaches that will be presented include checkpoint inhibition, IDO/TDO targeting, bispecifics, dendritic cell therapy and vaccination, in lectures delivered by several of the frontrunners in this rapidly evolving and exciting field.
- Andreas van Elzas, Aduro Biotech
- Benoît Vandeneynde, Ludwig Institute for Cancer Research
"IDO and TDO Targeting"
- Geert-Jan Boons, Utrecht University
- Yvette van Kooyk, VU University Medical Center
"Dendritic Cell Biology and Targeting"
- Jolanda de Vries, Radboud University Nijmegen
"Dendritic Cell Therapy"
- Huib Ovaa, University of Leiden
"Small Molecule Probes"
- Rob de Jong, Gen Mab
Organised by : Section Medicinal Chemistry, Royal Netherlands Chemical Society (KNCV) (The Netherlands)
Contact person: Dr. Peter Molenveld
ACS-MEDI-EFMC MEDICINAL CHEMISTRY FRONTIERS 2017 - Philadelphia (Sheraton Downtown), USA - June 25-28, 2017
The meeting, co-organized by the European Federation of Medicinal Chemistry and the American Chemical Society Division of Medicinal Chemistry, is intended to bring scientists working in the medicinal chemistry field together in order to share new and exciting results and we encourage attendees to bring poster presentations.
ACSMEDI-EFMC Frontiers 2017 Symposium is the sixth in the series initiated in Siena, Italy in 2007 and continued in Barcelona, Spain in 2009, Stockholm, Sweden in 2011, San Francisco, CA in 2013 and Antwerp, Belgium in 2015. Philadelphia provides a picturesque backdrop for this exciting conference, and we know you will have a scientifically rewarding and enjoyable stay.
Frontiers 2017 will take place in the Sheraton Philadelphia Downtown Hotel, located at 201 N. 17th Street St., located in the heart of Philadelphia. The Sheraton Philadelphia Downtown is in close proximity to historic Philadelphia, the Liberty Bell, the Reading Terminal Market and the Franklin Institute, making it an ideal location to enjoy the city, and to experience the latest research in medicinal chemistry.
The scientific program for Frontiers 2017 will feature sessions covering the latest advances in medicinal chemistry. Session topic areas include:
- Small Molecule Modulators of RNA
- Positive Allosteric Modulators
- Biased Agonism in GPCRs
- Targeting Regulated Cell Death in Drug Discovery
- Drug Discovery in Academia
- The Latest in Antivirals
- IO and Eoigenetics in Treating Cancer
37TH EDITION OF THE EUROPEAN SCHOOL OF MEDICINAL CHEMISTRY (ESMEC) - Urbino, Palazzo Battiferri - July 2-6, 2017
The Scientific Committee of the European School of Medicinal Chemistry (ESMEC, Urbino) and the European Federation for Medicinal Chemistry (EFMC) offers 13 scholarships (10 + 3) for the participation to the XXXVI edition of the school, scheduled from July 2 to July 6, 2017.
The scholarships, covering the registration fee and the full board accommodation, will be assigned to PhD students enrolled in Doctoral Schools held in one of the member countries of EFMC, excluding Italy.
A Committee formed by Prof. Jordi Gracia, representative of EFMC, Prof. Gilberto Spadoni and Prof. Marco Mor, members of the School’s Scientific Committee, will carry out the selection on the basis of the candidate scientific CV and research project.
This year the scientific programme includes the following topics:
- Polipharmacology and Multi-targeting paradigms in drug discovery: complexity against complexity
- Structures and models in drug design
- Peptides: from synthesis to applications
- Beyond PhD: building up an appealing scientific and professional profile.
Applicants are invited to fill in the enclosed form and to send it along with a CV, a motivation letter and the abstract of the research project, preferably by e-mail, stating in the subject box “ESMEC Grant Application”, within March 24th, 2017 to:
Prof. Marco Mor
Dipartimento di Scienze degli Alimenti e del Farmaco
Università degli Studi di Parma
Parco delle Scienze 27/A
43124 PARMA (I)
EFMC SESSION ON COMPUTER-AIDED DRUG DESIGN AT AIMECS 2017
Come and listen to the talks of Gisbert Schneider and Rebecca Wade during the EFMC Session, held at the AIMECS 2017 in Melbourne, Australia on July 23-26, 2017.
The Asian Federation for Medicinal Chemistry (AFMC) organises the AIMECS2017, the 11th in our series of International Medicinal Chemistry Symposia (AIMECS), alongside the Centenary Royal Australian Chemical Institute (RACI) Congress in July 2017 in Melbourne, Australia. The theme reflects this focus on Chemistry: Chemistry in Drug Discovery, Design & Development.
The program comprises several sessions organised or sponsored by Professional Societies and Journals with the following keynote speakers confirmed so far:
The American Chemical Society (ACS) sessions on Epigentic Targets:
Stuart Conway, Takayoshi Suzuki, Pat Woster
The European Federation of Medicinal Chemistry sessions on Computer-Aided Drug Design:
Gisbert Schneider, Rebecca Wade
Sessions sponsored by the ACS journals J Med Chem and ACS Med Chem Letts on Computer-Aided Drug Design:
Sessions sponsored by the same journals on Neglected Diseases: an Asian Perspective:
Paul Keller, Michael Pollastri
The RACI Plenary Speaker, Molly Stevens, will give a second keynote talk in a session on Regenerative Medicine and Biomaterials.
The AIMECS will take place on July 23-26, 2017 and the Medicinal Chemistry content of the Centenary Congress continues on Thursday and Friday, 27 and 28 July.
Why not register for those two days, as well!
EFMC GRANTS 2017
EFMC is funding grants for EFMC organised events with the aim to support the participation of young academic scientists.
Upon application, a limited number of full registration fees for EFMC-ISMC, EFMC-ASMC, ACSMEDI-EFMC Medicinal Chemistry Frontiers and up to 50% of the registration fee for the EFMC Short Courses or the EFMC Accredited School will be covered by EFMC.
To apply for an EFMC grant, please fill in the application form before the deadline and upload your CV, publication list, abstract, motivation letter and support letter from the supervisor.
Grant applications for the following events are open:
- 13th EFMC Short Course on Medicinal Chemistry - A Matter of Time; A Kinetic Perspective on Drug-Target Interactions
(deadline for application is March 1, 2017) - Link to the Event
- ACSMEDI-EFMC Medicinal Chemistry Frontiers 2017 Symposium
(deadline for application is March 20, 2017) - Link to the Event
- EFMC-ASMC'17 - International Symposium on Advances in Synthetic and Medicinal Chemistry
(deadline for application is April 10, 2017) - Link to the Event
- 4th EFMC Young Medicinal Chemist Symposium
(in combination with the EFMC-ASMC'17) - Link to the Event
Please be informed that following new EFMC regulations, only the members of an EFMC National Adhering Organisation will be allowed to apply for the EFMC grants.
NEWS FROM THE BIOLOGICAL AND MEDICINAL CHEMISTRY SECTOR (BMCS) OF THE ROYAL SOCIETY OF CHEMISTRY (RSC)
Exciting Symposia for your 2017 Diary! Abstract deadlines approaching fast so come along and present your research..
Fragments 2017 - 6th RSC-BMCS Fragment-based Drug Discovery meeting, Sunday to Tuesday, 5th to 7th March 2017 at the Parkhotel Schönbrunn, Vienna, Austria
REGISTRATION STILL OPEN!
The aim of this meeting will be to continue the focus on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programmes. The conference will include successful examples from all types of fragment-based approaches, including high concentration, NMR, SPR and X-ray screening
BMCS Mastering MedChem III, Wednesday, 22nd March 2017, Life Sciences Hub, Cardiff, UK
Call for poster abstracts will close on 28th February
Synopsis: This meeting is aimed at all those who wish to become better drug hunters and heed warnings from the past. In the main there are two types of drug discovery programmes: those that hit serious problems and those that are going to hit serious problems. The difference between success and failure is how we, as medicinal chemists, tackle and resolve the problems
The 2nd Symposium on Transporters in Drug Discovery and Development, Monday-Tuesday, 15th - 16th May 2017 at Burlington House, Piccadilly, London
Call for poster abstracts will close on 31st March 2017
Cell surface transporters play a key role in human health and disease, both through their impact on drug disposition and as therapeutic targets in their own right. This meeting continues on from the first, successfully held in 2014, and is anticipated to become part of a regular series. It should be of interest to medicinal chemists, DMPK scientists and other workers with interests on the impact of transporters on human health
NEWS FROM EUCHEMS – NEWSLETTER « CHEMISTRY IN EUROPE »
Chemistry in Europe (CiE) is the EuCheMS quarterly publication mainly intended for an audience of chemists. Its objective is to inform chemists about research and education in Europe, to provide updates from EuCheMS Member Organisations, and to look into policy-related developments.
To learn more and subscribe to EuCheMS’ newsletter, please follow the link www.euchems.eu/newsletters/chemistry-in-europe-2017-1/
EFMC ORGANISED EVENTS
EFMC SPONSORED EVENTS
EFMC SPONSORED SCHOOLS
Find us on social media